A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

Open Access UCL Research: A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter https://t.co/XYMZ00ZruF

$CGTX Findings from the SNAP study demonstrate that a single oral dose of CT1812 rapidly displaces Aβ oligomers from synapses. https://t.co/HCGuMjpHHl

...Given that toxic Aβ oligomers play a critical role in AD pathogenesis, these findings support continued clinical development of CT1812..." Learn more about the MOA of our lead candidate here https://t.co/lpQSp2jOFp

From our recent pub in @BioMedCentral journal Translational Neurodegeneration: "..early proof of principle that target engagement can be measured in patients after a single dose of CT1812...." https://t.co/YxznabXhYa